NCT02256852 is a Phase 2 clinical trial of QBKPN SSI in Non-Small Cell Lung Cancer, sponsored by Qu Biologics Inc..

Who is sponsoring NCT02256852?

NCT02256852 is sponsored by Qu Biologics Inc..

What drugs are being tested in NCT02256852?

Interventions in NCT02256852: QBKPN SSI.

What condition does NCT02256852 study?

NCT02256852 studies Non-Small Cell Lung Cancer.

Is NCT02256852 still recruiting?

NCT02256852 is currently completed. Last updated 18 February 2016.

Last reviewed 2016-02-18 · How we verify

NCT02256852

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label,Single Arm,Exploratory Study to Evaluate the Safety,Tolerability,Compliance and MOA,of QBKPN SSI in Subjects With 2 or More Second Primary Pre-invasive/Invasive Adenocarcinoma Following Surgical Resection of Stage I NSCLC

Completed Phase 2 Last updated 18 February 2016

What this trial tests

Phase 2 trial testing QBKPN SSI in Non-Small Cell Lung Cancer in 6 participants. Completed in 1 November 2015.

Timeline

1 December 2014

Primary endpoint
1 November 2015

1 November 2015

Quick facts

Lead sponsor	Qu Biologics Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	1 December 2014
Primary completion	1 November 2015
Estimated completion	1 November 2015
Sites	1 location across Canada

Drugs / interventions tested

QBKPN SSI — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Qu Biologics Inc. — full company profile →

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety, tolerability and compliance variables
Time frame: 16 weeks
Assess the number of adverse events and subject reported data

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive or invasive adenocarcinoma following surgical section of Stage 1 NSCLC.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies.
Liu X, Yin L, Shen S, Hou Y. · · 2023 · cited 75× · PMID 37013041 · DOI 10.1016/j.gendis.2021.09.006
Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.
Bazett M, Costa AM, Bosiljcic M, Anderson RM, et al · · 2018 · cited 12× · PMID 29399400 · DOI 10.1080/2162402x.2017.1398875
The 12th World Congress on Inflammation : 8-12 August, 2015 Seaport Hotel and World Trade Center, Boston, USA.
· 2015 · cited 3× · PMID 26208821 · DOI 10.1007/s00011-015-0839-4

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Qu Biologics Inc. trials

Trials by the same sponsor.

NCT03472690 — QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02256852 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qu Biologics Inc.
Last refreshed: 18 February 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02256852.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing